Neutrophils and T cells were isolated, stimulated and/or cultured for in vitro and in vivo regulation and function assays.
INTRODUCTION AND OBJECTIVES:
Although normally restricted to activated B and T-cells, CD70 has been shown to be overexpressed in several types of solid tumor types including RCC, specifically the clear cell phenotype (ccRCC), and may play a role in the inhibition of anti-tumor immune response. Here, we show that inhibiting CD-70 signaling by ccRCC cells using antibody blockade enhances the anti-tumor immune response and is thus an attractive novel immunotherapy target for the management of ccRCC as a monotherapy or in combination with PD-1/PD-L1 blockade.
METHODS: Surgically resected ccRCC tumor tissue was processed to generate matched sets of primary patient-derived cancer cell lines and tumor infiltrating lymphocytes (TILs). Patient derived ccRCC cells were co-cultured with autologous TILs to test the effect on TIL reactivity of CD70-blockade with and without combination therapy with Nivolumab as measured via IFN-g release and CD107a mobilization to the membrane.
RESULTS: Co-culture of patient-derived ccRCC cancer cell lines with autologous TILs in the presence of CD70-blockade resulted in significantly greater killer T-cell reactivity that correlated with CD-70 expression by the patient derived ccRCC cells. Notably, this elevated T-cell reactivity was observed in ccRCC patients suggesting efficacy of CD70-blockade is greatest in patients with ccRCC, in which CD70 is most highly expressed. Interestingly, combination therapy with Nivolumab showed a trend towards increased T-cell reactivity indicating that CD-70/PD-1 blockade may be an effective combination immunotherapy for ccRCC management.
CONCLUSIONS: Immune checkpoint blockade targeting the PD-1 immune checkpoint axis only benefits a fraction of patients with mRCC. Combination immunotherapy has been shown to improve RCC disease burden thereby demonstrating the need to identify other targets to enhance the immune response against RCC. High neutrophil-to-lymphocyte ratio (NLR) is considered to be a marker of inflammatory response and has been found to be associated with worse clinical outcomes. We aim to investigate the role of NLR in this setting and explore the differences in NLR among uRCC molecular subgroups.
METHODS: After IRB approval we queried our internal database. A total of 138 patients with uRCC, who had undergone molecular profiling, were identified. 103 patients with a complete blood count obtained at the time of diagnosis and comprehensive follow-up data were included. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count (in K/µl). We used non-parametric hypothesis testing with a pre-rejection alpha of 0.05 in all the analyses. Cancer-specific survival (CSS) was calculated from the time of initial pathologic diagnosis to the time of death or last followup. Survival estimates were computed using the Kaplan-Meier method, Cox regression models were used to evaluate the association with covariates of interest.
RESULTS: Our cohort included a total of 63 men and 40 women, the median age was 56.5 years (IQR: 44.5-68). The median follow-up time was 37.5 months. NF2-loss and mTOR-hyperactive subgroups were identified in 17 (17%) and 25 (24%) patients, respectively. The median NLR was 3.08 K/µl (IQR: 2.09-4.19), this value was used to categorize patients into low-and high-NLR groups. Patients in the high-NLR group had significantly worse CSS (Cox, p < 0.0001, HR 1.25, CI: 1.15-1.37, Fig.1a) . Regarding the molecular subgroups, the median NLR value was 3.64 K/µl (IQR: 2.77-4.6) in the NF2-loss group and 2.06 K/µl (IQR: 1.89-2.85) in the mTORhyperactive group; this difference was statistically significant (p[0.007, Fig.1b) . Interestingly, the median values of these groups differed significantly from the rest of the cohort (p[0.02 and p[0.03, respectively) .
CONCLUSIONS: We show that NLR is significantly associated with clinical outcomes. Furthermore, distinct uRCC subgroups differ considerably in relationship to this parameter.
